L Michael Weiss, MD
Gastroenterology · Clearwater, FLNPI 1215026158
Payments from drug & device makers
Across 761 payments — averaging $2192.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$328K
- AbbVie$264K
- E.r. Squibb & Sons, L.L.C.$243K
- Janssen Research & Development, LLC$239K
- Pfizer$115K
- Bristol Myers Squibb$59K
- plus $422K from 28 others
Across 2 payments — averaging $4429.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celltrion, Inc.$8K
- Eli Lilly$860
What the payments were for
- Consulting fees$1,71927%
- Food & beverage$4,57171%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 112 | $327,692 |
| AbbVie(2 entities) | 212 | $263,622 |
| E.r. Squibb & Sons, L.L.C. | 12 | $242,673 |
| Janssen Research & Development, LLC | 63 | $238,643 |
| Pfizer(2 entities) | 114 | $115,455 |
| Bristol Myers Squibb | 20 | $58,958 |
| Braintree Laboratories, Inc. | 11 | $57,905 |
| Ironwood Pharmaceuticals, Inc | 10 | $57,349 |
| Genentech, Inc. | 25 | $55,207 |
| Roche Products Limited | 34 | $53,230 |
| Bausch Health US, LLC | 36 | $46,495 |
| Amgen | 9 | $42,274 |
| AstraZeneca | 9 | $36,756 |
| Shire North American Group Inc | 8 | $24,027 |
| Eli Lilly | 4 | $20,862 |
| F. Hoffmann-la Roche AG | 5 | $17,248 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $7,000 |
| Celltrion, Inc. | 1 | $1,719 |
| Johnson & Johnson | 24 | $666 |
| Madrigal Pharmaceuticals | 6 | $203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $196 |
| Gilead | 8 | $166 |
| Lilly USA, LLC | 3 | $69 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Regeneron Healthcare Solutions, Inc. | 3 | $56 |
| Novo Nordisk | 2 | $52 |
| Celltrion USA Inc. | 2 | $52 |
| Sanofi | 1 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $26 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Stryker | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$125
- Skyrizi$118
- Non-Covered Product$110
How this compares
$1,668,813 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 11 | $490,780 |
| StelaraUstekinumab | 12 | $327,460 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 82 | $13,348 |
| Mesalamine | 18 | $7,225 |
| Esomeprazole Magnesium | 58 | $3,932 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 19 | $3,280 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $1,010 |
| Pantoprazole Sodium | 70 | $893 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $742 |
| Omeprazole | 68 | $632 |
| Famotidine | 30 | $439 |
| Prednisone | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $327,692 | $490,78011 claims |
| Johnson & JohnsonStelara | $666 | $327,46012 claims |
| Braintree Laboratories, Inc.Sutab | $57,905 | $13,34882 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $26 | $3,28019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Clearwater
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
- Henry LevineOrlando$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.